163 related articles for article (PubMed ID: 35980273)
1. Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer.
Wang S; Wang S; Zhang X; Meng D; Xia Q; Xie S; Shen S; Yu B; Hu J; Liu H; Yan W
RNA Biol; 2022 Jan; 19(1):1007-1018. PubMed ID: 35980273
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
3. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
[TBL] [Abstract][Full Text] [Related]
4. Alternative Splicing: A New Therapeutic Target for Ovarian Cancer.
Yao S; Yuan C; Shi Y; Qi Y; Sridha R; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338211067911. PubMed ID: 35343831
[No Abstract] [Full Text] [Related]
5. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
6. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
Sun D; Zhao X; Yu Y; Li W; Gu P; Zhi Z; Xu D
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35137909
[TBL] [Abstract][Full Text] [Related]
8. Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer.
AZhaTi B; Wu G; Zhan H; Liang W; Song Z; Lu L; Xie Q
World J Surg Oncol; 2022 Jul; 20(1):231. PubMed ID: 35820925
[TBL] [Abstract][Full Text] [Related]
9. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration.
Zhang D; Lu W; Zhuo Z; Mei H; Wu X; Cui Y
Discov Oncol; 2022 Aug; 13(1):78. PubMed ID: 35988113
[TBL] [Abstract][Full Text] [Related]
10. Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma.
Wan Q; Sang X; Jin L; Wang Z
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098099
[TBL] [Abstract][Full Text] [Related]
11. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
Zhang D; Zou D; Deng Y; Yang L
J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
[TBL] [Abstract][Full Text] [Related]
12. Alternative splicing acts as an independent prognosticator in ovarian carcinoma.
Ouyang Y; Xia K; Yang X; Zhang S; Wang L; Ren S; Zhou H; Liu Y; Tang F
Sci Rep; 2021 May; 11(1):10413. PubMed ID: 34001978
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
14. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
15. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
Zhang D; Zhang W; Sun R; Huang Z
Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
[TBL] [Abstract][Full Text] [Related]
16. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data.
Wu HY; Peng ZG; He RQ; Luo B; Ma J; Hu XH; Dang YW; Chen G; Pan SL
Int J Oncol; 2019 Aug; 55(2):425-438. PubMed ID: 31268164
[TBL] [Abstract][Full Text] [Related]
17. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
[TBL] [Abstract][Full Text] [Related]
18. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
Front Genet; 2020; 11():534. PubMed ID: 32595697
[TBL] [Abstract][Full Text] [Related]
19. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
Zhu J; Chen Z; Yong L
Gynecol Oncol; 2018 Feb; 148(2):368-374. PubMed ID: 29191436
[TBL] [Abstract][Full Text] [Related]
20. Identification of prognostic alternative splicing signatures in uveal melanoma.
Xie X; Zheng X; Xie T; Cai J; Yao Y
Int Ophthalmol; 2021 Apr; 41(4):1347-1362. PubMed ID: 33479809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
